Anticoagulant: Difference between revisions
imported>Robert Badgett |
imported>Robert Badgett m (→See also) |
||
| Line 34: | Line 34: | ||
==See also== | ==See also== | ||
* [[ | * [[Coagulation]] | ||
==External links== | ==External links== | ||
Revision as of 04:54, 25 January 2008
Anticoagulants are "agents that prevent blood clotting".[1] They may be used to prevent embolism and thromboembolism.
Vitamin K antagonists
Warfarin
Warfarin is a commonly used oral anticoagulant that interferes with the Vitamin K dependent coagulation co-factors.
Heparin
Details of the usage of heparin are available in clinical practice guidelines by the American College of Chest Physicians[2]:
Direct thrombin inhibitors
Direct thrombin inhibitors bind directly to thrombin.[3]
- Argatroban is for treating heparin-induced thrombocytopenia (HIT)
- Bivalirudin is a recombinant protein
- Dabigatran
- Desirudin
- Hirudin is a recombinant protein for treating heparin-induced thrombocytopenia (HIT)
- Lepirudin
- Ximelagatran is a recombinant protein that is an oral direct thrombin inhibitor
Factor Xa inhibitors
Idraparinux is a synthetic derivative of heparin that has a long half life that allows once-weekly dosage. A randomized controlled trial compared idraparinux to warfarin and found that idraparinux is equivalent for deep venous thrombosis but is inferior for pulmonary embolism.[4]
Warfarin combined with heparin
Warfarin combined with heparin did not benefit survivors of acute myocardial infarction in a randomized controlled trial.[5]
Warfarin combined with heparin reduced events, but increased bleeding, among survivors of acute myocardial infarction in a randomized controlled trial.[6]
References
- ↑ Anonymous (2024), Anticoagulants (English). Medical Subject Headings. U.S. National Library of Medicine.
- ↑ Hirsh J, Raschke R (2004). "Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy". Chest 126 (3 Suppl): 188S-203S. DOI:10.1378/chest.126.3_suppl.188S. PMID 15383472. Research Blogging.
- ↑ Di Nisio M, Middeldorp S, Büller HR (2005). "Direct thrombin inhibitors". N. Engl. J. Med. 353 (10): 1028–40. DOI:10.1056/NEJMra044440. PMID 16148288. Research Blogging.
- ↑ Buller HR, Cohen AT, Davidson B, et al (2007). "Idraparinux versus standard therapy for venous thromboembolic disease". N. Engl. J. Med. 357 (11): 1094–104. DOI:10.1056/NEJMoa064247. PMID 17855670. Research Blogging.
- ↑ Fiore LD, Ezekowitz MD, Brophy MT, Lu D, Sacco J, Peduzzi P (2002). "Department of Veterans Affairs Cooperative Studies Program Clinical Trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: primary results of the CHAMP study". Circulation 105 (5): 557–63. PMID 11827919. [e]
- ↑ Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H (2002). "Warfarin, aspirin, or both after myocardial infarction". N. Engl. J. Med. 347 (13): 969–74. DOI:10.1056/NEJMoa020496. PMID 12324552. Research Blogging.
See also
External links
The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines